Current Report Filing (8-k)
28 January 2023 - 9:07AM
Edgar (US Regulatory)
0001630113
false
0001630113
2023-01-23
2023-01-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): January 23, 2023
BIOTRICITY,
INC. |
(Exact
Name of Registrant as Specified in Its Charter) |
Nevada |
(State
or Other Jurisdiction of Incorporation) |
001-40761 |
|
30-0983531 |
(Commission
File Number) |
|
(IRS
Employer Identification No.) |
275
Shoreline Drive, Suite 150
Redwood City, California 94065
(Address
of Principal Executive Offices)
(650)
832-1626
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, 0.001 |
|
BTCY |
|
NASDAQ
Capital Markets |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
On
January 23rd. 2023, Biotricity Inc. (the “Company”) received $2,000,000 in cash proceeds from an existing investor.
The Company and the investor are in the process of finalizing the final documentation but Company expects to issue the investor a promissory
note with matures in 18-months and has an accrued interest rate of 10%. The
promissory note will contain other customary provisions.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
Date:
January 27, 2023
|
BIOTRICITY,
INC. |
|
|
|
/s/
Waqaas Al-Siddiq |
|
Waqaas
Al-Siddiq |
|
Chief
Executive Officer |
Biotricity (NASDAQ:BTCY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biotricity (NASDAQ:BTCY)
Historical Stock Chart
From Jul 2023 to Jul 2024